Robert Kridel

Robert Kridel

University of Toronto

H-index: 39

North America-Canada

About Robert Kridel

Robert Kridel, With an exceptional h-index of 39 and a recent h-index of 36 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Lymphoma, Cancer.

His recent articles reflect a diverse array of research interests and contributions to the field:

Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication

The pathobiology of select adolescent young adult lymphomas

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population

Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience

Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

PARP14 is a novel target in STAT6 mutant follicular lymphoma

Robert Kridel Information

University

Position

Princess Margaret Cancer Centre - UHN

Citations(all)

6440

Citations(since 2020)

4278

Cited By

3870

hIndex(all)

39

hIndex(since 2020)

36

i10Index(all)

50

i10Index(since 2020)

48

Email

University Profile Page

Google Scholar

Robert Kridel Skills & Research Interests

Lymphoma

Cancer

Top articles of Robert Kridel

Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication

Journal of Clinical Pathology

2024/1/5

The pathobiology of select adolescent young adult lymphomas

2023/11

Robert Kridel
Robert Kridel

H-Index: 27

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population

2023/11/1

Wei Xu
Wei Xu

H-Index: 19

Robert Kridel
Robert Kridel

H-Index: 27

Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma

Journal of Clinical Oncology

2023/9/1

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience

Haematologica

2023/4/4

Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma

Leukemia & Lymphoma

2022/12/6

Robert Kridel
Robert Kridel

H-Index: 27

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

American Journal of Hematology

2022/12

PARP14 is a novel target in STAT6 mutant follicular lymphoma

Leukemia

2022/9

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60

Cancers

2022/2/12

Robert Kridel
Robert Kridel

H-Index: 27

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program

Haematologica

2022

Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

American Journal of Hematology

2022

DNA methylation-based classification of small B-cell lymphomas: a proof-of-principle study

The Journal of Molecular Diagnostics

2021/12/1

Combined EZH2 inhibition and IKAROS degradation leads to enhanced antitumor activity in diffuse large B-cell lymphoma

Clinical Cancer Research

2021/10/1

Treatment resistance in diffuse large B-cell lymphoma

2021/8

Robert Kridel
Robert Kridel

H-Index: 27

Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma

haematologica

2021/5/1

Predicting early progression in follicular lymphoma

Annals of Lymphoma

2021

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

British Journal of Haematology

2020/9

Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma

Leukemia & lymphoma

2020/7/28

Cathepsin S regulates antigen processing and T cell activity in non-Hodgkin lymphoma

Cancer cell

2020/5/11

Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

Cell reports

2020/5/5

See List of Professors in Robert Kridel University(University of Toronto)

Co-Authors

academic-engine